JP2005501857A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501857A5
JP2005501857A5 JP2003521237A JP2003521237A JP2005501857A5 JP 2005501857 A5 JP2005501857 A5 JP 2005501857A5 JP 2003521237 A JP2003521237 A JP 2003521237A JP 2003521237 A JP2003521237 A JP 2003521237A JP 2005501857 A5 JP2005501857 A5 JP 2005501857A5
Authority
JP
Japan
Prior art keywords
compound
sodium salt
temperature
fusion
crystalline sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003521237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501857A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/025675 external-priority patent/WO2003016315A1/en
Publication of JP2005501857A publication Critical patent/JP2005501857A/ja
Publication of JP2005501857A5 publication Critical patent/JP2005501857A5/ja
Withdrawn legal-status Critical Current

Links

JP2003521237A 2001-08-17 2002-08-13 Hivインテグラーゼ阻害剤のナトリウム塩 Withdrawn JP2005501857A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31337301P 2001-08-17 2001-08-17
PCT/US2002/025675 WO2003016315A1 (en) 2001-08-17 2002-08-13 Sodium salt of an hiv integrase inhibitor

Publications (2)

Publication Number Publication Date
JP2005501857A JP2005501857A (ja) 2005-01-20
JP2005501857A5 true JP2005501857A5 (https=) 2006-01-05

Family

ID=23215462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003521237A Withdrawn JP2005501857A (ja) 2001-08-17 2002-08-13 Hivインテグラーゼ阻害剤のナトリウム塩

Country Status (7)

Country Link
US (1) US6924282B2 (https=)
EP (1) EP1430058A1 (https=)
JP (1) JP2005501857A (https=)
AR (1) AR036256A1 (https=)
CA (1) CA2456206A1 (https=)
DO (1) DOP2002000449A (https=)
WO (1) WO2003016315A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425440C (en) * 2000-10-12 2010-04-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
WO2003077857A2 (en) * 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
CN100418948C (zh) * 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
US20070185007A1 (en) 2003-09-19 2007-08-09 Haolun Jin Aza-quinolinol phosphonate integrase inhibitor compounds
EP1742642B1 (en) * 2004-04-14 2008-10-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
KR20090077813A (ko) 2006-09-29 2009-07-15 아이데닉스 파마슈티칼스, 인코포레이티드 Hiv 억제제로서의 거울상이성질체적으로 순수한 포스포인돌

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
US5681832A (en) 1995-02-17 1997-10-28 The United States Of America As Represented By The Department Of Health And Human Services Aroylaniline compounds, pharmaceutical compositions, and methods of using same to inhibit viral activity
US5945431A (en) 1996-03-15 1999-08-31 Biochem Therapeutics Incorporated Cytomegalovirus inhibiting compounds
EP0927164A1 (en) * 1996-09-10 1999-07-07 PHARMACIA & UPJOHN COMPANY 8-hydroxy-7-substituted quinolines as anti-viral agents
KR100567649B1 (ko) 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
DE69828284T2 (de) 1997-06-30 2005-12-08 Nippon Kayaku K.K. Naphthyridinderivate oder salze davon
PL338783A1 (en) 1997-08-25 2000-11-20 Neurogen Corp Substituted 4-oxo-naphtyridin-3-carboxamides as ligands of cerebral gaba receptors
DE69831506T2 (de) 1997-12-22 2006-06-29 Pharmacia & Upjohn Co. Llc, Kalamazoo 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
US6306891B1 (en) 1998-06-03 2001-10-23 Merck & Co., Inc. HIV integrase inhibitors
US6380249B1 (en) 1998-06-03 2002-04-30 Merck & Co., Inc. HIV integrase inhibitors
US6262055B1 (en) 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
JP2003503386A (ja) 1999-06-25 2003-01-28 メルク エンド カムパニー インコーポレーテッド 1−(芳香族またはヘテロ芳香族置換)−3−(ヘテロ芳香族置換)−1,3−プロパンジオン類およびそれの使用
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2425440C (en) * 2000-10-12 2010-04-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
EP1441734B1 (en) 2001-10-26 2007-02-28 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
NZ533057A (en) 2001-10-26 2005-11-25 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase

Similar Documents

Publication Publication Date Title
JP2021530565A5 (https=)
JP2006519818A5 (https=)
JP2020128376A5 (https=)
JP2009534468A5 (https=)
JP2006526031A5 (https=)
RU2013145518A (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
JP2011527333A5 (https=)
JP2009533410A5 (https=)
JP2005503386A5 (https=)
JP2007532560A5 (https=)
JP2021501151A5 (https=)
JP2011500658A5 (https=)
JP2008525416A5 (https=)
JP2010514806A5 (https=)
CA2632585A1 (en) Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene and processes for preparing said compound
JP2023036708A5 (https=)
JP2010514807A5 (https=)
JP2012533550A5 (https=)
JP2005520803A5 (https=)
JP2013538849A5 (https=)
CA2540768A1 (en) Pyrazolo and imidazo-pyrimidine derivatives
JP2013521301A5 (https=)
JP2008507494A5 (https=)
JP2005511697A5 (https=)
CA2526991A1 (en) Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor